Comparing Oncologic Outcomes and Toxicity for Combined Modality Therapy vs. Carbon-Ion Radiotherapy for Previously Irradiated Locally Recurrent Rectal Cancer
Elizabeth B. Jeans(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Hirotoshi Takiyama(National Institutes for Quantum Science and Technology), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Daniel K. Ebner(National Institutes for Quantum Science and Technology), Hiroshi Tsuji(National Institutes for Quantum and Radiological Science and Technology), Anita Mahajan(The University of Texas MD Anderson Cancer Center), William S. Harmsen(Mayo Clinic), Kaitlin Qualls(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Danielle A. Cunningham(Mayo Clinic), Shigeru Yamada(National Institutes for Quantum Science and Technology), Kellie L. Mathis(Twitter (United States)), Robert L. Foote(Mayo Clinic), Krishan R. Jethwa(Mayo Clinic), Mark R. Waddle(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Eric J. Dozois(Mayo Clinic)
Cited by 14
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632